• E Karantali, G Katsikaki, S Chatzikonstantinou, and S Papagiannopoulos.
• 3Department of Neurology, Aristotle University of Thessaloniki, G.Papanikolaou General Hospital, Thessaloniki, Greece.
• Hippokratia. 2019 Oct 1; 23 (4): 179-180.

BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated disease of the peripheral nervous system characterized by motor weakness, sensory symptoms, areflexia, and specific electrophysiological findings. Rarely, Anti-Tumor Necrosis Factor-alpha (anti-TNFa) agents, which are used as a treatment for immune-mediated diseases, can cause neurological adverse effects on the central nervous system, as well as peripheral nervous system demyelination.Case ReportWe describe the case of a 63-year-old woman with ankylosing spondylitis who developed chronic inflammatory demyelinating polyneuropathy after infliximab initiation. Considering the absence of other trigger agents from her medical history and the symptom onset, we assume that the development of CIDP is secondary to the anti-TNFa treatment.ConclusionAlthough demyelinating neurological complications of anti-TNF are rare, pharmacovigilance is required. HIPPOKRATIA 2019, 23(4): 179-180.Copyright 2019, Hippokratio General Hospital of Thessaloniki.

2 keywords...

hide…